Clinical trials: Meniere Disease
Hearing Loss, Sudden, Hearing Loss, Ototoxic
Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss
This study is a prospective, randomized pilot study. To verify an efficacy and safety of the Intratympanic drug delivery vehicle, patients who have not responded to the existing standard treatment will be enrolled.
- Conditions
- Hearing Loss, Sudden, Hearing Loss, Ototoxic, Hearing Loss, Noise-Induced, Meniere Disease
- Trial name
- NCT04766853
- Testing
- Dexamethasone, Hyaluronic acid
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Seoul National University Hospital
Meniere's Disease
Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets
A multicenter, randomized, open-label clinical study with a concurrent control group to assess the effectiveness and safety of combined therapy with Isobide solution and Meniace tablets compared to monotherapy with Meniace…
- Trial name
- NCT02718846
- Testing
- Meniace, Isobide
- Volunteers
- 220 people
- Sponsor
- Alvogen Korea
Meniere's Disease
A 6-Month Extension Study of OTO-104 in Meniere's Disease
This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections.
- Trial name
- NCT02768662
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease, Stress
Stress Management Therapy for Meniere's Disease
Attacks in Meniere's disease, characterized by vertigo and hearing loss, are well known to occur repeatedly under stressed environment.
- Trial name
- SMT (NCT01099046)
- Testing
- Lifestyle
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Osaka University
Meniere's Disease
Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent
This is a pilot study of patients with clinical symptoms of Ménière's disease using injection of diluted magnetic resonance imaging (MRI) contrast agent into the ear to evaluate inner ear structures.
- Trial name
- NCT02080312
- Testing
- Magnevist (gadopentetate dimeglumine)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Diego
Sleep Disorders
Sleep Disorders and Their Impact on Patients With Ménière's Disease
Ménière's disease was first described by Prosper Ménière in 1861 as a balance disorder originating in the inner ear. It is diagnosed based on a characteristic clinical triad of low-frequency hearing loss, tinnitus, and vertigo…
- Trial name
- SoM (NCT07299578)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Autoimmune Inner Ear Disease
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
- Trial name
- NCT01950312
- Testing
- gevokizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- XOMA (US) LLC
Meniere Disease, Hearing Loss, Sensorineural
Meniere Disease and Hearing Aids
Patients with unilateral Meniere Disease often a distortion that causes difficulties to provide hearing aids to these patients. Those patients have two main problems: disorders in noise comprehension due to interaural threshold…
- Trial name
- MMA (NCT05582148)
- Testing
- Hearing aids fitting
- Volunteers
- 10 people
- Sponsor
- University Hospital, Grenoble
Autoimmune Inner Ear Disease, Meniere's Disease
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
A Phase II randomized, placebo controlled study design of anakinra (Kineret) in corticosteroid-resistant or intolerant Meniere's disease (CR-MD)and corticosteroid-resistant or intolerant autoimmune inner ear disease (CR-AIED)…
- Trial name
- NCT03587701
- Testing
- Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwell Health
Meniere's Disease
Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy
This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's…
- Trial name
- NCT00160238
- Testing
- Betahistine 24 mg bid (Betaserc)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Solvay Pharmaceuticals
Vertigo, Meniere's Disease
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
Aim of this work was to assess the role of polymorphisms belonging to genes involved in the regulation of ionic homeostasis in Caucasian patients with Ménière Disease (MD) and compare results with a cohort of patients affected by…
- Conditions
- Vertigo, Meniere's Disease, Vestibular Migraine
- Trial name
- Menière09 (NCT07518069)
- Testing
- a blood withdrawal will be obtained, blood withdrawal
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Meniere's Disease, Benign Paroxysmal Positional Vertigo
CAVA: Dizziness Trial
Clinical investigation of a medical device (CAVA) for recording eye movements. Patients suffering from diagnosed dizziness conditions will wear the device for 23 hours a day, for 30 days.
- Conditions
- Meniere's Disease, Benign Paroxysmal Positional Vertigo, Recurrent Vestibulopathy, Vestibular Migraine
- Trial name
- CAVA (NCT04026516)
- Testing
- CAVA Device
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
Meniere's Disease, Ménière's Disease
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
- Trial name
- NCT06859788
- Testing
- Ebselen
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Intratympanic Steroid Injection, Idiopathic Sudden Sensorineural Hearing Loss
Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection
Intratympanic steroid injections are an accepted treatment for Meniere's disease and idiopathic sudden sensorineural hearing loss. This treatment is typically performed using local topical anesthesia.
- Conditions
- Intratympanic Steroid Injection, Idiopathic Sudden Sensorineural Hearing Loss, Meniere Disease
- Trial name
- NCT04794842
- Testing
- Tetracaine 5% drops, Phenol 90% concentration
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Our Lady of the Lake Hospital
Ménière's Disease
Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers
The goal of this pharmakokinetic trial is to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone.
- Trial name
- PK-BesT (NCT05938517)
- Testing
- Betahistine dihydrochloride, Selegiline-hydrochloride
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Meniere Disease, Allergic Rhinitis
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
- Conditions
- Meniere Disease, Allergic Rhinitis, Vertigo
- Trial name
- NCT04815187
- Testing
- Montelukast
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- House Ear Institute
Meniere Disease
Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of…
- Trial name
- NCT04218123
- Testing
- Venlafaxine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Sudden Sensorineural Hearing Loss, Meniere Disease
Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
Evaluation of the diagnostic and prognostic efficacy of nuclear magnetic resonance imaging in patients with acute sensorineural hearing loss or in patients suffering from probable or definite MD.
- Conditions
- Sudden Sensorineural Hearing Loss, Meniere Disease, Ménière's Vertigo, Meniere's Disease Aggravated
- Trial name
- MRI_SSHL/MD (NCT06278129)
- Testing
- Vestibular myogenic potentials
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Meniere's Disease, Meniere Disease
Expanded Access Protocol for SPI-1005
The purpose of this protocol is to facilitate expanded access ("compassionate use") of SPI-1005 to Meniere's disease (MD) or sudden sensorineural hearing loss (SSNHL) patients who cannot gain access through ongoing clinical…
- Conditions
- Meniere's Disease, Meniere Disease, Meniere´s Disease, Meniere's Disease Aggravated
- Trial name
- NCT07873281
- Testing
- Ebselen
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere's Disease
OTO-104 for Meniere's Disease
The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.
- Trial name
- NCT01084525
- Testing
- OTO-104 (steroid) 3 mg, OTO-104 (steroid) 12 mg
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- Otonomy, Inc.